- Home
- DSM vs JSPR Comparison
DSM vs JSPR Comparison
Compare DSM & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSM
- JSPR
- Stock Information
- Founded
- DSM 1989
- JSPR 2018
- Country
- DSM United States
- JSPR United States
- Employees
- DSM N/A
- JSPR N/A
- Industry
- DSM Investment Managers
- JSPR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DSM Finance
- JSPR Health Care
- Exchange
- DSM Nasdaq
- JSPR Nasdaq
- Market Cap
- DSM 303.5M
- JSPR 342.2M
- IPO Year
- DSM N/A
- JSPR N/A
- Fundamental
- Price
- DSM $6.14
- JSPR $22.81
- Analyst Decision
- DSM
- JSPR Strong Buy
- Analyst Count
- DSM 0
- JSPR 10
- Target Price
- DSM N/A
- JSPR $74.86
- AVG Volume (30 Days)
- DSM 161.7K
- JSPR 216.7K
- Earning Date
- DSM 01-01-0001
- JSPR 11-07-2024
- Dividend Yield
- DSM 3.97%
- JSPR N/A
- EPS Growth
- DSM N/A
- JSPR N/A
- EPS
- DSM N/A
- JSPR N/A
- Revenue
- DSM N/A
- JSPR N/A
- Revenue This Year
- DSM N/A
- JSPR N/A
- Revenue Next Year
- DSM N/A
- JSPR N/A
- P/E Ratio
- DSM N/A
- JSPR N/A
- Revenue Growth
- DSM N/A
- JSPR N/A
- 52 Week Low
- DSM $4.69
- JSPR $4.00
- 52 Week High
- DSM $6.05
- JSPR $31.01
- Technical
- Relative Strength Index (RSI)
- DSM 60.80
- JSPR 56.60
- Support Level
- DSM $6.00
- JSPR $19.12
- Resistance Level
- DSM $6.04
- JSPR $23.60
- Average True Range (ATR)
- DSM 0.05
- JSPR 1.58
- MACD
- DSM 0.02
- JSPR -0.02
- Stochastic Oscillator
- DSM 100.00
- JSPR 60.00
About DSM BNY Mellon Strategic Municipal Bond Fund Inc.
BNY Mellon Strategic Municipal Bond Fund, Inc. is a diversified closed-end management investment company. Its investment objective is to seek to maximize current income exempt from federal income tax to the extent consistent with the preservation of capital.
About JSPR Jasper Therapeutics Inc.
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.